This Website uses cookies to provide you with a personalized browsing experience. By using this Website, you agree to our use of cookies as explained in our Privacy Policy. Please read our Privacy Policy for more information on how we use cookies and how you can manage them.


Cipla has been at the forefront of innovation for inhalation therapy in India. The Company has played a leading role in educating the nation on inhalation therapy and over the coming years we will continue to work on topics such as patient awareness, acceptance, compliance and usage, physician training, medical camps and counselling. Strongly focused on access and affordability, Cipla Respiratory continued to strengthen its efforts through the “BreatheFree” patient awareness and education programs across markets, dedicated to making a difference to both patients and medical practitioners.

Over the last 40 years, the Company has been focused on bringing this innovation to markets across the globe. Today, Cipla Respiratory products are available in over 100 countries. Cipla - the top pharmaceutical company in India, offers the world’s largest portfolio of inhalation products, with 27 molecules and combinations across a range of devices, to suit individual patient needs. The Company manufactures Metered Dose Inhalers (pMDIs), dry powder inhalers, nasal sprays, nebulisers and a range of inhaled accessory devices. The company has five manufacturing facilities dedicated to respiratory products and is currently the third largest manufacturer of pMDIs in the world.

This year Cipla Respiratory launched several inhalation products across European markets. In parallel, significant progress has been made on the development of critical new products for the U.S. and other priority markets. The team of world-class specialists continues to collaborate seamlessly across functions to drive Cipla Respiratory to new frontiers. Competition remains aggressive and we need to continue to maintain our agility to retain our leadership.

During the year under review, Cipla acquired 60% stake in Jay Precision Pharmaceuticals Private Limited. As Cipla aims to make a strong foray in overseas markets, de-risking the Respiratory devices supply through backward integration is key to fix the foundation. The deal provides in-house access to technical know-how of current and future device design, development and manufacturing.

Cipla now has end-to-end capability across respiratory care covering the value chain from API, formulation, device development and manufacturing to medical and patient education.

Highlights of Cipla’s devices

  • Transparent Rotahaler1 – The world’s first transparent dry powder inhaler
  • Revolizer – Novel single-dose capsule dry powder inhaler
  • Multi-haler – Multi-dose dry powder inhaler
  • Autohaler2 – First breath-actuated metered dose inhaler in India
  • Zerostat and Zerostat VT – Non-static spacers
  • Babymask and Infantmask – For delivery of inhaled medications to young children
  • Nasal sprays – A variety of nasal sprays for treatment of nasal allergy
  • The widest range of Dry Powder Inhaler devices

Our DPIs have been developed to ensure consistent dose delivery through patient-friendly devices – Rotacaps and Multi-halers comprising the actives and a high grade excipient.

The Rotahaler, launched in 1996, heralded the era of patient-friendly inhalation therapy. Transparent, simple to use, and with consistency of dose, it has transformed the lives of millions of asthmatics.

The Revolizer is a new generation, patient-friendly dry powder inhaler, exclusively developed by Cipla. It is probably the easiest device to use. The patient simply opens the Revolizer, inserts the Rotacap, shuts the device and inhales. It provides accurate dosing, even at low inspiratory flow rates. A revolution in inhalation therapy indeed.

The Multi-haler is a multiple dose dry powder inhaler device with an inbuilt dose counter. It disperses individual pre-metered doses from a blister and needs just a single step for use. A simple action of sliding the mouthpiece cover punctures a blister to release the drug powder, which is then inhaled through the mouthpiece. It gives precise and consistent dosing.

Cipla will soon launch an innovative inhaler which will bring important benefits for physicians, patients and healthcare providers on managing Obstructive Airway Disease (OAD). The new inhaler is called Synchrobreathe which is a novel, breath-actuated inhaler (BAI) with a dose counter.

The range of Metered-Dose Inhaler devices

Cipla MDIs are designed to deliver accurate and consistent dosing by using the most sophisticated metered dose valves, canisters and actuators.

The Autohaler is a new advance in MDI therapy. It is a unique Breath-Actuated Inhaler (BAI) and overcomes the key problem of the MDI, which is co-ordination of actuation with inhalation. It can be activated at low inspiratory flow rates and can be easily used by children and by those who suffer airflow obstruction and arthritis. Cipla is the first company in the world to market combination therapy through the Autohaler.

Range of Spacers and related devices

Spacers (sometimes also called holding chambers) are devices that hold the medication for a few seconds after it has been released from the MDI.

They overcome the ‘co-ordination’ problem and also slow down the aerosol spray before it reaches the mouth, thus allowing the propellants to evaporate and larger particles to settle in the spacer. This reduces the incidence of oral thrush and the amount of drug that is swallowed, thus minimising side-effects.

The Zerostat Spacer is a static-free, non-transparent spacer without a valve. Being static-free it results in much higher drug deposition and enhances the effectiveness of MDI therapy.

The Zerostat VT Spacer is a unique transparent, static-free spacer with a valve. It ensures that more quantity of the drug reaches the lungs following inhalation, with the result that patients receive a high and consistent quantity of medication, dose after dose.

The Babymask and Infantmask make it easy to deliver inhaled medicines to young children using an inhaler and a spacer device. It is made of comfortable, soft, clear silicon and is reusable. It fits snugly and is also equipped with an exhalation vent for easy breathing.

The Huf Puf Kit consists of a Zerostat VT Spacer attached to a Babymask and can be used with any Cipla MDI. It is easy-to-use with no need to dismantle and re-assemble the kit every time. It has an attractive and child-friendly pack and is convenient to carry.

All our devices have obtained CE certification and help the world breathe better.

1 - Rotahaler is a trademark used in India only. Outside India it is known as DPhaler.

2 - Imported from 3M Pharmaceuticals, UK.